CN110240654A - 结合cd73的抗体-药物偶联物 - Google Patents

结合cd73的抗体-药物偶联物 Download PDF

Info

Publication number
CN110240654A
CN110240654A CN201810506111.8A CN201810506111A CN110240654A CN 110240654 A CN110240654 A CN 110240654A CN 201810506111 A CN201810506111 A CN 201810506111A CN 110240654 A CN110240654 A CN 110240654A
Authority
CN
China
Prior art keywords
seq
antibody
ser
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810506111.8A
Other languages
English (en)
Chinese (zh)
Inventor
余科
金锐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fudan University
Original Assignee
Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fudan University filed Critical Fudan University
Priority to EP19763891.9A priority Critical patent/EP3783025A4/en
Priority to CN201980001728.7A priority patent/CN110869393B/zh
Priority to CA3093327A priority patent/CA3093327C/en
Priority to PCT/CN2019/077369 priority patent/WO2019170131A1/zh
Priority to JP2020546414A priority patent/JP7330996B2/ja
Priority to US16/978,995 priority patent/US12024565B2/en
Publication of CN110240654A publication Critical patent/CN110240654A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201810506111.8A 2018-03-07 2018-05-24 结合cd73的抗体-药物偶联物 Pending CN110240654A (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP19763891.9A EP3783025A4 (en) 2018-03-07 2019-03-07 TARGETED CD73 ANTIBODY AND ANTIBODY DRUG CONJUGATE, METHOD FOR ITS PRODUCTION AND USES THEREOF
CN201980001728.7A CN110869393B (zh) 2018-03-07 2019-03-07 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
CA3093327A CA3093327C (en) 2018-03-07 2019-03-07 Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof
PCT/CN2019/077369 WO2019170131A1 (zh) 2018-03-07 2019-03-07 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
JP2020546414A JP7330996B2 (ja) 2018-03-07 2019-03-07 Ｃｄ７３を標的とする抗体および抗体－薬物複合体、その製造方法と使用
US16/978,995 US12024565B2 (en) 2018-03-07 2019-03-07 Targeted CD73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018101883518 2018-03-07
CN201810188351 2018-03-07

Publications (1)

Publication Number Publication Date
CN110240654A true CN110240654A (zh) 2019-09-17

Family

ID=67882908

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810506111.8A Pending CN110240654A (zh) 2018-03-07 2018-05-24 结合cd73的抗体-药物偶联物
CN201980001728.7A Active CN110869393B (zh) 2018-03-07 2019-03-07 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980001728.7A Active CN110869393B (zh) 2018-03-07 2019-03-07 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途

Country Status (5)

Country Link
US (1) US12024565B2 (https=)
EP (1) EP3783025A4 (https=)
JP (1) JP7330996B2 (https=)
CN (2) CN110240654A (https=)
CA (1) CA3093327C (https=)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110575548A (zh) * 2018-06-07 2019-12-17 中国科学院上海药物研究所 靶向于cd73的抗体-药物偶联物及其制法和用途
CN111714642A (zh) * 2020-06-18 2020-09-29 复旦大学 Cd73抗体-药物偶联物的应用
CN112285361A (zh) * 2020-09-27 2021-01-29 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN113045659A (zh) * 2021-03-18 2021-06-29 上海近岸科技有限公司 抗cd73人源化抗体
CN113398242A (zh) * 2021-06-04 2021-09-17 浙江大学 一种抗体耦联药物及其应用
CN113440610A (zh) * 2021-08-30 2021-09-28 山东大学 共载cd73抗体和阿霉素的脂质体及其制备方法和应用
CN113506508A (zh) * 2021-08-07 2021-10-15 河北师范大学 一种超疏水物理不可克隆性结构色防伪标签以及其制备方法
CN113527489A (zh) * 2020-04-22 2021-10-22 中山康方生物医药有限公司 抗cd73的抗体及其用途
CN113842467A (zh) * 2020-06-28 2021-12-28 达石药业(广东)有限公司 用于抗体与药物偶联体（adc）制备的中间体及其制备方法和应用
WO2022037531A1 (zh) * 2020-08-17 2022-02-24 中山康方生物医药有限公司 抗cd73的抗体及其用途
CN114269389A (zh) * 2019-11-05 2022-04-01 礼新医药科技(上海)有限公司 靶向紧密连接蛋白18.2的抗体药物偶联物
WO2022068898A1 (zh) * 2020-09-29 2022-04-07 迈威(上海)生物科技股份有限公司 一种双取代桥连抗体偶联药物的制备方法
WO2022105881A1 (en) * 2020-11-20 2022-05-27 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Anti-cd73 antibody, antibody-drug conjugate, and use thereof
WO2022152144A1 (zh) * 2021-01-13 2022-07-21 上海华奥泰生物药业股份有限公司 结合cd73的蛋白及其应用
WO2022205316A1 (en) * 2021-04-01 2022-10-06 Shanghai Allygen Biologics Co., Ltd. Targeting conjugates comprising effector molecules and uses thereof
CN115175917A (zh) * 2019-12-31 2022-10-11 启德医药科技（苏州）有限公司 药物缀合物及其应用
CN116178546A (zh) * 2022-10-13 2023-05-30 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用
WO2023109962A1 (zh) * 2021-12-17 2023-06-22 三生国健药业（上海）股份有限公司 结合人cd73的抗体、其制备方法和用途
CN116769034A (zh) * 2022-08-12 2023-09-19 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
WO2023174213A1 (zh) * 2022-03-14 2023-09-21 上海华奥泰生物药业股份有限公司 抗体药物偶联物及其应用
WO2023206242A1 (zh) * 2022-04-28 2023-11-02 江苏中新医药有限公司 无钩状效应的抗人cd73单克隆抗体
WO2023246325A1 (zh) * 2022-06-22 2023-12-28 复旦大学 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途
CN117567632A (zh) * 2023-11-27 2024-02-20 福州迈新生物技术开发有限公司 抗cd73蛋白单克隆抗体及其制备方法和应用
WO2025011590A1 (zh) * 2023-07-11 2025-01-16 清华大学 一种抗体衍生物及其应用
WO2025025190A1 (zh) * 2023-08-03 2025-02-06 贝达药业股份有限公司 抗cd73抗体及其应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111434688A (zh) * 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
CN112442132A (zh) * 2019-09-05 2021-03-05 复旦大学 靶向肿瘤的重组双功能融合蛋白及其应用
CN113061177B (zh) * 2020-12-31 2022-07-01 浙江大学 一种cd73酶活性相关的抗原表位及针对该表位的特异性抗体的制备方法
EP4299589A4 (en) * 2021-02-24 2025-06-11 Novoprotein Scientififc Inc. HUMAN ANTI-CD73 ANTIBODY AND ITS USE
CN117157098A (zh) * 2021-06-22 2023-12-01 荣昌生物制药(烟台)股份有限公司 一种药物组合及其用途
CN120035606A (zh) * 2022-05-26 2025-05-23 天境生物科技(上海)有限公司 一种治疗实体瘤的方法
WO2023249425A1 (ko) * 2022-06-22 2023-12-28 ㈜지아이이노베이션 항-cd73 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
CN119019557B (zh) * 2024-10-28 2024-12-20 北京伟杰信生物科技有限公司 一种检测白介素29的抗体组合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3218406T4 (da) * 2014-11-10 2024-12-09 Medimmune Ltd Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf
MY189836A (en) * 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
KR102577959B1 (ko) 2015-06-25 2023-09-14 다우 글로벌 테크놀로지스 엘엘씨 낮은 헥산 추출물을 갖는 에틸렌계 폴리머
WO2017028823A1 (zh) * 2015-08-20 2017-02-23 复旦大学 靶向于组织因子的抗体、其制备方法和用途
US11130817B2 (en) * 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
WO2017100670A1 (en) * 2015-12-09 2017-06-15 Corvus Pharmaceuticals, Inc. Humanized anti-cd73 antibodies
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110575548A (zh) * 2018-06-07 2019-12-17 中国科学院上海药物研究所 靶向于cd73的抗体-药物偶联物及其制法和用途
CN114269389A (zh) * 2019-11-05 2022-04-01 礼新医药科技(上海)有限公司 靶向紧密连接蛋白18.2的抗体药物偶联物
CN115175917A (zh) * 2019-12-31 2022-10-11 启德医药科技（苏州）有限公司 药物缀合物及其应用
CN113527489B (zh) * 2020-04-22 2024-04-26 中山康方生物医药有限公司 抗cd73的抗体及其用途
CN113527489A (zh) * 2020-04-22 2021-10-22 中山康方生物医药有限公司 抗cd73的抗体及其用途
CN111714642A (zh) * 2020-06-18 2020-09-29 复旦大学 Cd73抗体-药物偶联物的应用
CN113842467A (zh) * 2020-06-28 2021-12-28 达石药业(广东)有限公司 用于抗体与药物偶联体（adc）制备的中间体及其制备方法和应用
WO2022037531A1 (zh) * 2020-08-17 2022-02-24 中山康方生物医药有限公司 抗cd73的抗体及其用途
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN112285361A (zh) * 2020-09-27 2021-01-29 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
WO2022068898A1 (zh) * 2020-09-29 2022-04-07 迈威(上海)生物科技股份有限公司 一种双取代桥连抗体偶联药物的制备方法
CN114306633A (zh) * 2020-09-29 2022-04-12 迈威(上海)生物科技股份有限公司 一种双取代桥连抗体偶联药物的制备方法
WO2022105881A1 (en) * 2020-11-20 2022-05-27 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Anti-cd73 antibody, antibody-drug conjugate, and use thereof
WO2022152144A1 (zh) * 2021-01-13 2022-07-21 上海华奥泰生物药业股份有限公司 结合cd73的蛋白及其应用
CN113045659A (zh) * 2021-03-18 2021-06-29 上海近岸科技有限公司 抗cd73人源化抗体
WO2022205316A1 (en) * 2021-04-01 2022-10-06 Shanghai Allygen Biologics Co., Ltd. Targeting conjugates comprising effector molecules and uses thereof
CN113398242A (zh) * 2021-06-04 2021-09-17 浙江大学 一种抗体耦联药物及其应用
CN113398242B (zh) * 2021-06-04 2022-04-29 浙江大学 一种抗体耦联药物及其应用
CN113506508B (zh) * 2021-08-07 2022-08-23 河北师范大学 一种超疏水物理不可克隆性结构色防伪标签以及其制备方法
CN113506508A (zh) * 2021-08-07 2021-10-15 河北师范大学 一种超疏水物理不可克隆性结构色防伪标签以及其制备方法
CN113440610A (zh) * 2021-08-30 2021-09-28 山东大学 共载cd73抗体和阿霉素的脂质体及其制备方法和应用
CN113440610B (zh) * 2021-08-30 2021-12-28 山东大学 共载cd73抗体和阿霉素的脂质体及其制备方法和应用
WO2023109962A1 (zh) * 2021-12-17 2023-06-22 三生国健药业（上海）股份有限公司 结合人cd73的抗体、其制备方法和用途
WO2023174213A1 (zh) * 2022-03-14 2023-09-21 上海华奥泰生物药业股份有限公司 抗体药物偶联物及其应用
WO2023206242A1 (zh) * 2022-04-28 2023-11-02 江苏中新医药有限公司 无钩状效应的抗人cd73单克隆抗体
WO2023246325A1 (zh) * 2022-06-22 2023-12-28 复旦大学 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途
WO2023246623A1 (zh) * 2022-06-22 2023-12-28 复旦大学 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途
CN116769034B (zh) * 2022-08-12 2024-01-02 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
CN116769034A (zh) * 2022-08-12 2023-09-19 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
CN116903744A (zh) * 2022-08-12 2023-10-20 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
CN116903744B (zh) * 2022-08-12 2024-03-08 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
CN116178546A (zh) * 2022-10-13 2023-05-30 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用
CN116178546B (zh) * 2022-10-13 2024-06-18 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用
WO2025011590A1 (zh) * 2023-07-11 2025-01-16 清华大学 一种抗体衍生物及其应用
WO2025025190A1 (zh) * 2023-08-03 2025-02-06 贝达药业股份有限公司 抗cd73抗体及其应用
CN117567632A (zh) * 2023-11-27 2024-02-20 福州迈新生物技术开发有限公司 抗cd73蛋白单克隆抗体及其制备方法和应用

Also Published As

Publication number Publication date
JP7330996B2 (ja) 2023-08-22
CA3093327C (en) 2024-01-16
US12024565B2 (en) 2024-07-02
EP3783025A4 (en) 2022-02-23
EP3783025A1 (en) 2021-02-24
CN110869393B (zh) 2022-08-30
JP2021516960A (ja) 2021-07-15
CN110869393A (zh) 2020-03-06
CA3093327A1 (en) 2019-09-12
US20210024646A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
CN110869393B (zh) 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
CN110770256B (zh) 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途
US12290505B2 (en) Tissue factor-targeted antibody-drug conjugate
WO2019170131A1 (zh) 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
CN110575547B (zh) 靶向于tf的抗体-药物偶联物及其制法和用途
JP6892826B2 (ja) Ｃｄ４８抗体及びその複合体
TW202203978A (zh) 電荷可變連接子
CN110577600B (zh) 靶向gpc3的抗体-药物偶联物及其制备方法和用途
JP2021513844A (ja) グリピカン３抗体およびそのコンジュゲート
CN110575548A (zh) 靶向于cd73的抗体-药物偶联物及其制法和用途
CN108101825A (zh) 用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途
WO2024051463A1 (zh) 能够特异性结合ror1的抗体、其偶联药物及其制备方法和应用
KR20250137203A (ko) 항체 약물 접합체
CN117304316A (zh) 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途
CN118667006A (zh) 靶向ror1的抗体、包含其的抗体偶联药物、制备方法和用途
JP2022500454A (ja) 抗葉酸受容体抗体コンジュゲートによる併用療法
HK40017733B (en) Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof
HK40017733A (en) Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof
HK40016110B (en) Axl-targeting antibody, antibody-drug conjugate, preparation method therefor, and use thereof
HK40016110A (en) Axl-targeting antibody, antibody-drug conjugate, preparation method therefor, and use thereof
CN120774988A (zh) 一种连接子、抗体药物偶联物及其制备方法
CN121079107A (zh) 一种连接子、抗体药物偶联物及其制备方法
CN113754764A (zh) 抗dog-1抗体、缀合物、药物组合物、药物制剂及其用途
HK40007884A (en) Anti-trailr2 antibody-toxin-conjugate and pharmaceutical use thereof in anti-tumor therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190917

WD01 Invention patent application deemed withdrawn after publication